Company profile

AKI Therapeutics A/S is a preclinical biotechnological company that focuses 100% on developing an effective, specific treatment for acute kidney injury. The company’s drug candidate is a pioneering concept within this treatment area, which presents one of the biggest and most important challenges in the field of current intensive medical care.

There are currently no alternative treatments.

Acute kidney injury (AKI), formerly known as acute renal failure, is a serious complication that may affect over 30% of all critically ill patients e.g. with septicemia, septic shock or multiple traumas, as well as a considerable proportion of patients that have undergone cardiopulmonary bypass surgery. The annual incidence of new cases worldwide is in the order of 13 million, with a rising tendency. In addition, there is a further rise in patient numbers as a result of the COVID-19 pandemic.

Our Corporate governance

Financial Reports